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Abstract: In recent years, great interest has been devoted to finding alternative sources for human
stem cells which can be easily isolated, ideally without raising ethical objections. These stem cells
should furthermore have a high proliferation rate and the ability to differentiate into all three germ
layers. Amniotic fluid, ordinarily discarded as medical waste, is potentially such a novel source
of stem cells, and these amniotic fluid derived stem cells are currently gaining a lot of attention.
However, further information will be required about the properties of these cells before they can be
used for therapeutic purposes. For example, the risk of tumor formation after cell transplantation
needs to be explored. The tumor suppressor protein p53, well known for its activity in controlling
Cell Prolif.eration and cell death in differentiated cells, has more recently been found to be also active
in amniotic fluid stem cells. In this review, we summarize the major findings about human amniotic
fluid stem cells since their discovery, followed by a brief overview of the important role played by
p53 in embryonic and adult stem cells. In addition, we explore what is known about p53 in amniotic
fluid stem cells to date, and emphasize the need to investigate its role, particularly in the context of
cell tumorigenicity.
Keywords: amniotic fluid cells; embryonic stem cells; mesenchymal stem cells; p53; proliferation;
differentiation
1. Introduction
Stem cells are present throughout the embryonic development and in adult organs. A coordinated
control of stem cell self-renewal and differentiation is essential for maintaining tissue and organ
homeostasis. Since 1980, a huge amount of work has been invested into the analysis of embryonic
stem (ES) cells. These cells show incredible features like i) the ability to be expanded in vitro while
maintaining an undifferentiated state, and ii) pluripotency, which means that the cells possess the
capability to differentiate into every cell type of the adult body [1]. Because of these properties, ES
cells may potentially be used in regenerative medicine in the future. However, the use of ES cells in
stem cell therapy is also raising ethical concerns since they are isolated from human embryos, and
they possess the risk of tumor formation in vivo. Pertaining to this issue, Yamanaka and Takahashi
showed that stem cells with properties similar to ES cells can be generated from mouse fibroblasts by
simply introducing combinations of genes like Oct4, Nanog, c-Myc, and Klf4 [2]. They designated these
cells as “induced pluripotent stem cells” or “iPS” cells. Although iPS cells have clinical potential as a
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source of cells for regenerative medicine similar to ES cells, transplanting differentiated cells derived
from iPS cells into patients remains a grave concern, as the genomic integrity of these cells and the
safety of the patient is still an issue [3]. A second problem is the low efficiency and slow kinetics of iPS
cell generation in vitro [3]. To overcome these limitations, researchers started to look for alternative
sources of stem cells. This endeavor gave rise to research in the field of perinatal stem cells.
Perinatal stem cells can be derived from postembryonic tissues, which include the tissues sourced
at the time of birth, but also comprise the time period from the 16th week of gestation through the
neonatal period [4,5]. These tissues include the amniotic fluid, the placenta, placental membranes
(amnion, chorion and Wharton jelly) and umbilical cord [6–10]. At the time of birth, these tissues are
usually discarded as “biological waste”. As these tissues are anyway discarded, harvesting stem cells
from these sources is a simple and non-invasive method for obtaining stem cells that could be used
for therapy. Interest in perinatal stem cells was particularly initiated, when Kaviani and colleagues
reported in 2001 about the use of these cells for tissue engineering and for the surgical repair of
congenital anomalies in the perinatal period [11]. In addition to being easily accessible, perinatal stem
cells can be isolated, expanded, and differentiated in vitro [12–17]. It is therefore anticipated that these
cells can serve as a novel source and an alternative to human ES cells for research and therapy.
The amnion encloses the amniotic cavity containing the amniotic fluid, a protective and
nutrient-containing liquid for the developing fetus [18]. It is mainly composed of water, electrolytes,
chemical substances, nutrients, and cells shed from the growing embryo [19,20]. Among the
heterogeneous population of amniotic fluid cells, a class of multipotent cells, the amniotic fluid
stem (AFS) cells have been identified. These cells share characteristics of ES and adult stem cells [21].
Most interestingly, and in contrast to ES cells, the AFS cells are not tumorigenic when injected into
immune-compromised animals [14,22]. This property makes these cells particularly attractive for
clinicians and researchers in the field of regenerative medicine. A comparison between the main
features of ES and AFS cells is shown in Table 1.
Table 1. Comparison between human embryonic stem (ES) cells and human amniotic fluid stem
(AFS) cells.
Features Human ES Cells Human AFS Cells
Source of cells Inner cell mass of a blastocyststage embryo
Amniotic fluid from second or
third trimester of pregnancy
Plasticity Pluripotent Multipotent
Ease of cultivation Requirement of MEF for feedersand the presence of bFGF
Cultivation without feeders but in
presence of bFGF
Doubling time 24 to 96 h Approximate 36 h
Marker expression:
Pluripotency Oct4, Nanog, Sox-2, Klf4
Oct4, Nanog (low), Sox2 (low),
Klf4 (low)
Cell Surface Antigens
Mesenchymal
SSEA1, SSEA3, SSEA4, Tra-1-60,
Tra-1-81
SSEA4, CD-117 (c-kit), CD90,
CD105, CD73, CD13, CD29, CD44,
CD146
In vitro differentiation potential All three germ layers(under specific culture conditions)
All three germ layers
(under specific culture conditions)
Ability to form embryoid body Yes Yes
Tumorigenic in vivo Yes No
Ethical concerns Yes No
Legal restrictions Yes No
Therapeutic animal model testing Yes Yes
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By using various factors and methods, AFS cells can also be reprogrammed into iPS cells [23–25].
Human AFS-iPS cells express pluripotency markers such as alkaline phosphatase, Oct4, Sox2, SSEA4,
etc., and can be continuously propagated in vitro while maintaining their normal karyotype [26].
As AFS cells have a stem cell-like characteristic, ectopic expression of the transcription factor Oct4
is sufficient to make them fully pluripotent, at least under certain conditions [27]. In a recent study,
AFS cells from human second trimester amniotic fluid were also transfected with modified messenger
RNAs of Oct4, Klf4, Sox2, Lin28, and c-Myc to induce a pluripotent state, and then differentiated
into functional cardiomyocytes using inhibitors of glycogen synthase kinase 3 (GSK3) and Wnt [25].
Cells from the first trimester that have been selected for the surface antigen c-kit can furthermore be
fully reprogrammed to pluripotency without transfecting ectopic factors when they are cultured on
matrigel in cell culture medium that has been supplemented with the histone deacetylase inhibitor,
valproic acid [28].
The lack of tumorigenesis after transplantation is an interesting feature of AFS cells, although no
information is available regarding the underlying mechanisms. Important clues could be gathered by
investigating in AFS cells the activities and functions of crucial cell cycle regulators, like the tumor
suppressor gene p53.
p53 is one of the most well-known and most intensively investigated tumor suppressor proteins.
A lot of work has already been done on investigating the role of p53 in ES cells and other adult stem
cells and it has been established that apart from its traditional tumor suppressor function, p53 is also
reported to be involved in controlling Cell Prolif.eration, self-renewal, and differentiation of stem
cells [29].
2. Phenotypic Characterization of Amniotic Fluid Stem Cells
Amniocentesis is routinely performed between 16–18 weeks of pregnancy. The collected amniotic
fluid is used for prenatal genetic testing and as a source of AFS cells. Different approaches and protocols
have been used to isolate AFS cells [8,30,31]. These isolation protocols can be distinguished into
i) a one-step culture protocol; in this procedure the primary amniocyte culture is left undisturbed for
seven [32,33] to twenty [34] days without any changes in the medium; ii) a two-step culture protocol;
in this approach the non-adherent amniocytes are collected on the fifth or seventh day after isolation
and kept until further analysis is completed. After that, the cells are cultured in the appropriate
medium [31,35]; iii) a procedure where the amniocytes are selected for a specific marker, for example
for CD117 (c-Kit receptor) [8,36] and iv) a short-term culture method; specimens are centrifuged and
incubated in Mesencult or Chung medium. After three days, non-adherent cells are discarded, and
fresh medium is added. Thereafter cells can be cultured [37] or clonally expanded [38] (Figure 1).
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Based on morphological and growth characteristics, human amniotic fluid cells are grouped
into three main categories: i) amniocytes or amniotic fluid specific AF-type cells; this type of cell
comprises about 60% of the amniotic fluid cells. ii) Epitheloid E-type cells; this type of cells make
about 34% of the amniotic fluid cells. iii) Fibroblastic F-type cells; about 6% of the amniotic fluid
cells belong to this type of cells [39–41]. The first and second group of cells are usually present at the
beginning of cultivation. The third group of cells appears later, when the cells have been cultured
already for some time, while the E-type cells disappear when the amniotic fluid cells are taken into
culture [41–43]. The majority of the AFS cells share a multipotent mesenchymal phenotype similar to
adult mesenchymal stem cells [8,31,34,44–48]. In consistency with their multipotent phenotype, AFS
cells express the pluripotency markers Oct4, SSEA-4, and Nanog at the RNA and protein levels, as
well as the stem cell markers vimentin and alkaline phosphatase [49,50]. Other stem cell markers like
SSEA-3 and TRA-1-81 are, however, usually not present in AFS cells, indicating that these cells can
most likely not be regarded as fully undifferentiated cells [8,28]. Interestingly, cells isolated from some
amniotic fluid cultures express neural markers, such as Nestin, βIII-tubulin, GFAP and NEFH [22].
Approximately 1% of the AFS cells express the surface antigen c-kit (CD117), a receptor tyrosine
kinase type III, which plays a role in cell survival, proliferation, and differentiation [8]. Some authors
regard only the c-kit positive cells as the stem cell population in a heterogeneous AFS cell culture [8].
However, both the c-kit-positive and the c-kit-negative amniotic fluid cells have similar morphology
and proliferation characteristics and are able to differentiate along the osteogenic and adipogenic
lineages under specific culture conditions. The c-kit-positive cells, however, show high Oct-4, Sox2,
and Nanog expression and also show a higher ability to differentiate into myocardial-like cells than
c-kit-negative cells, indicating that the c-kit-positive cells may have more stem cell properties than
the c-kit-negative cells [17]. The fibroblast-shaped cell population of amniotic fluid cells furthermore
expresses the mesenchymal markers CD90, CD105, CD73, and CD166, while the cells are negative for
the hematopoietic markers CD45, CD34, and CD14 [14]. Based on the fact that these cells express some
but not all stem cell markers and several mesenchymal markers, some researchers consider AFS cells
to be mesenchymal stem cells [14].
AFS cells maintain a normal karyotype and stable telomeres when taken into culture, even after
over 200 population doublings [49], yet other properties like expression of stem cell pluripotency
markers, expression of specific proteins during differentiation, immune regulation and endothelial
regenerative potential after differentiation may vary with gestational stage [51–53].
One of the most important qualities of AFS cells is that they are non-tumorigenic when transplanted
into immunocompromised mice [8]. Although AFS cells possess several similarities with ES cells
(Table 1) and the transcriptome of AFS cells from the first trimester with passage numbers between 15 and
20 shows about 80% identity with that of human ES cells [54], AFS cells differ from ES cells in this crucial
feature. Even seven months after the intravenous injection of AFS cells into mice, the animals had no
detectable tumors [55]. Although many groups have evidenced the non-tumorigenic property of these
cells, detailed investigations on this inability have not been reported so far. Tumorigenicity is usually
associated with chromosomal alterations, and since clonal human AFS cell lines lack chromosomal
alterations, it is likely that their chromosomal stability is responsible or at least contributes to the fact
that these cells do not form tumors. However, when iPS cells are generated by ectopic expression of
Oct4 in AFS cells, tumors are formed within 2 months [27].
Likewise, AFS cells also do not form teratomas after in vivo transplantation [22]. Even 11 weeks
after transplantation of cultured human AFS cells into immunodeficient mice, teratomas were not
observed while under the same conditions human ES cells caused teratoma formation after only
3–4 weeks [22]. On careful consideration, teratoma formation is closely linked with pluripotency.
However, AFS cells are not pluripotent, and it is most likely that the fact that AFS cells are not
pluripotent makes teratoma formation impossible. This idea is supported by the observation that
certain in vitro culture conditions equip AFS cells with the ability to form teratomas. This ability of
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AFS cells to form teratomas comes along with an upregulation of pluripotency associated genes like
Oct4, Nanog, and Sox2 [28].
3. Differentiation Potential of Amniotic Fluid Stem Cells
Since the discovery of AFS cells, several groups have been exploring their differentiation potential.
Even before it was known that the amniotic fluid contains Oct4-positive stem cell-like cells, Streubel and
coworkers had demonstrated the expression of skeletal muscle proteins when amniotic fluid cells
were cultured in the supernatant of rhabdomyosarcoma cell lines [56]. After this first observation
of a differentiation potential of AFS cells, in the presence of various inducing factors, these cells
were reported to be able to differentiate into multiple lineages including hematopoietic, neurogenic,
osteogenic, chondrogenic, adipogenic, renal and hepatic lineages and to form fibroblasts, adipocytes,
and osteocytes (Figure 2) [8,35,36,44,45,57–64].
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Guan and colleagues showed that undifferentiated human AFS cells express several cardiac
genes (transcription factor mef2, the gap junction connexin43 and H- and N-cadherin), acquire a
cardiomyocyte-like phenotype after 24-h incubation with 5-aza-2′-deoxycytidine (5-AZA-dC) and
develop mechanical and electrical connections with neonatal rat cardiomyocytes when co-cultured [65].
Rat AFS cells were induced towards cardiomyogenic differentiation by co-culturing with neonatal
rat cardiomyocytes [66] and under specific conditions mouse AFS cells were shown to differentiate
into cardiomyocyte-like beating cells, although with a very low efficiency [67]. More recently it was
demonstrated that a subset of amniotic fluid cells that were positive for CD90, called cardiopoietic AF
cells, might differentiate toward the cardiac lineage giving rise to cardiomyocyte-like cells [68].
AFS cells have furthermore been demonstrated to form embryoid bodies when cultured in
suspension, accompanied by a decrease in the expression of the pluripotency stem cell marker Oct4 and
nodal, a marker for the self-renewal potential of ES cells, followed by the induction of differentiation
markers like Flk1 (fetal liver kinase 1) for endothelial cells, E-cadherin for epithelial cells, Pax 6 (paired
box protein 6) for ectodermal cells, TBXT (T-box transcription factor T) and HBE1 (hemoglobin subunit
epsilon 1) for mesodermal cells, and GATA4 for endodermal cells [69].
Similar to ES cells and iPS cells, AFS cells are capable of differentiating into primordial germ cells
when cultured under appropriate culture conditions and through formation of embryoid bodies [70,71].
Thus, AFS cells may even be used to study the mechanisms of early gametogenesis.
In summary, the enormous efforts in the past years by various groups to exploit and investigate
differentiation of AFS cells have yielded positive results and demonstrate that amniotic fluid cells have
a broad differentiation potential.
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4. p53, the Guardian of the Genome
Functionally, p53 is a transcription factor that elicits its cellular activity mostly through
transcriptional activation of target genes. However, besides its primary function as a transcription
factor, p53 can also promote apoptosis independent of transcription via direct interaction with pro-
and anti-apoptotic proteins [72]. Pertaining to its anti-proliferative activity, p53 is under tight control.
The activity of p53 is regulated by its protein abundance as well as by its post-translational modifications.
It is well established that p53 degradation is largely achieved through the ubiquitin-proteasome
pathway [73], but a role for other proteolytic enzymes such as calpain has also been reported [74].
The short half-life of p53 ensures that its abundance in non-stressed cells is low. However, when
its activity is required, p53 is protected from degradation and accumulates to high levels [75,76].
The major regulator of p53 levels is the oncoprotein Mdm2, to which p53 is connected by a negative
feedback loop. The p53 protein binds to the mdm2 gene and activates its transcription, and the resultant
Mdm2 binds to p53, blocks its activity, and mediates the proteolytic degradation of p53 [77]. As a main
negative regulator of p53, Mdm2 is fine-tuned by a group of protein partners that bind to Mdm2
in a context- and cell- dependent manner. One of these proteins is Mdm4 (Mouse double minute
4 or MdmX) [78], an Mdm2 homolog which oligomerizes with Mdm2 and increases Mdm2’s E3
ligase activity [79]. This Mdm2/Mdm4 oligomerization allows Mdm2 to more efficiently regulate p53
levels and activity [80]. Additionally, apart from Mdm2 and Mdm4 other E3 ubiquitin ligases like
constitutive photomorphogenesis protein (COP1) or p53-induced protein with a RING-H2 domain
(Pirh2) regulate protein levels and activities of p53 in a variety of physiological conditions, and in
response to cellular changes induced by stress [81]. COP1 and Pirh2 synergistically function with the
Mdm2/Mdm4 complex to inhibit p53’s activities, including p53’s transcriptional activity [80].
p53 is part of a multiple gene family that also includes p63 and p73, as well as several splice
variants of the three proteins [82,83]. p53 splice variants were first identified in 1980s in humans and
mice [84,85]. Although p53, p63 and p73 share structural, biochemical and biological homologies and
regulate a common set of target genes, they control different cellular activities. For instance, the p53
protein has a fundamental role in growth control and maintenance of genomic integrity, whereas p63
is essential for epidermal morphogenesis and limb development [86]. On the other hand, mice that
are deficient in p73 have abnormalities of the nervous system and suffer from chronic infections and
inflammation [86].
The role and effector functions of p53 however are context dependent and such context dependence
is affected by cell type, genetic background of the cell, cell microenvironment, and nature of stress
the cell is undergoing. Because p53 is such a critical cellular protein, multiple mechanisms have
evolved to modulate its activity. The existing strategies consist of manipulating p53’s transcriptional or
translational control by altering the level of p53 mRNA, by changing its posttranslational modifications,
by altering p53’s half-life by freeing wild type p53 from MDM2, and by altering p53’s intracellular
localization [87].
5. p53 in Stem Cells
Similar to differentiated cells, p53 becomes activated in stem cells in response to DNA damage,
where p53 activates the promoters of its canonical target genes including Bax and Puma resulting in
apoptosis [88]. In addition, p53 suppresses the expression of Nanog and Oct4 after DNA damage, thus
evoking differentiation of these cells [89–91]. Both activities contribute to the maintenance of genomic
stability in stem cells.
However, p53 is not only active in stem cells after DNA damage. A few years ago, it was
discovered that p53 is also active in non-stressed stem cells. Yet, the anti-proliferative activity of p53 is
compromised in these cells and p53 instead directs a transcriptional program that is highly reminiscent
to that of tumor-derived mutant p53 [92].
More recent studies implicate p53 also into the plasticity of stem cells. Here, p53 seems to be
involved in the regulation of the self-renewal of stem cells as well as for the onset of differentiation
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(Figure 3). The emerging non-canonical roles of p53 in stem cells have been nicely summarized
earlier [29] and were also reviewed very recently by Olivos and Mayo [93].
Int. J. l. ci. , 19, x 7 of 15 
(Figure 3). The emerging non-canonical roles of p53 in stem cells have been nicely summarized 
earlier [29] and were also reviewed very recently by Olivos and Mayo [93].  
 
Figure 3. Diverse roles of p53 in stem cells. 
The first evidence for a role of p53 in embryos dates back to the 1980′s, when this protein was 
found highly expressed in primary cell cultures obtained from 12–14 day old mouse embryos but not 
in 16-day-old mouse embryos [94]. A year later it was reported that the amount of p53 protein 
decreased significantly during embryogenesis [95]. This observation was further supported by many 
other groups who also observed a significant decrease in the amount of p53 mRNA and protein 
during differentiation [90,96–98]. Interestingly, Sabapathy et al. observed a conformational change in 
p53 during differentiation resulting in loss of functional activity that allows the differentiating cells 
to escape from apoptosis [97]. Lin and coworkers reported that in murine ES cells, p53 directly 
represses the stem cell marker Nanog [90], a protein known to promote dedifferentiation of 
astrocytes into cancer stem-like cells [99]. Subsequently, it was shown that spontaneous 
differentiation of human ES cells is significantly reduced when p53 abundance is decreased and that 
disrupting or inactivating p53 increases the production of iPS cells, a feature of p53 that is conserved 
from mice to men [100–102]. Few years later, another group found out that p53 actively promotes 
differentiation of ES cells by inducing the expression of miR-34a and miR-145. The latter one operates 
as a direct repressor of the pluripotency factors Oct4, Klf4, Lin28A, and Sox2 upon retinoic 
acid-mediated differentiation of ES cells [103]. Likewise, treatment of human ES cells with Nutlin, a 
small molecule that binds to the p53 antagonist Mdm2 and inhibits p53 degradation resulting in p53 
accumulation promoted the differentiation of stem cells [104]. Maimets and coworkers assumed that 
the main mechanism that is responsible for the differentiation of human ES cells after activation of 
p53 is the inhibition of S phase entry into the cell cycle due to the induction of the cell cycle inhibitor 
p21 by p53. Other studies showcasing p53−/− human ES cells further confirmed the suppressive 
activity of p53 for stem cell pluripotency [102,105,106]. Of note, silencing Oct4 in human ES cells led 
to the activation of p53 and in consequence to ES cell differentiation [107]. Silencing of Oct4, 
furthermore, reduced the expression of Sirt1, a deacetylase known to inhibit p53 activity, leading to 
increased acetylation of p53 at lysine 120 and 164 which leads to stabilization and activation of p53 in 
human ES cells [107]. A very recent report identified a regulatory network in mesendodermal 
differentiation of mouse and human ES cells involving other members of the p53 family (p63 and 
p73) [108]. They showed p53, p63, and p73 are crucial for the activation of eomesodermin, Foxa2 
(forkhead box A2) and goosecoid which support the differentiation into mesendoderm of ES cells in 
vitro and in the embryo. p53 family members directly control the activation of these genes by 
governing the cooperation of Wnt and nodal which are interdependent in driving mesendodermal 
differentiation of pluripotent cells [108].  
Figure 3. Diverse roles of p53 in stem cells.
The first evidence for a role of p53 in embryos dates back to the 1980’s, when this protein was
found highly expressed in primary cell cultures obtained from 12–14 day old mouse embryos but
not in 16-day-old mouse embryos [94]. A year later it was reported that the amount of p53 protein
decreased significantly during embryogenesis [95]. This observation was further supported by many
other groups who also observed a significant decrease in the amount of p53 mRNA and protein during
differentiation [90,96–98]. Interestingly, Sabapathy et al. observed a conformational change in p53
during differentiation resulting in loss of functional activity that allows the differentiating cells to
escape from apoptosis [97]. Lin and coworkers reported that in murine ES cells, p53 directly represses
the stem cell marker Nanog [90], a protein known to promote dedifferentiation of astrocytes into cancer
stem-like cells [99]. Subsequently, it was shown that spontaneous differentiation of human ES cells
is significantly reduced when p53 abundance is decreased and that disrupting or inactivating p53
increases the production of iPS cells, a feature of p53 that is conserved from mice to men [100–102].
Few years later, another group found out that p53 actively promotes differentiation of ES cells by
inducing the expression of miR-34a and miR-145. The latter one operates as a direct repressor of
the pluripotency factors Oct4, Klf4, Lin28A, and Sox2 upon retinoic acid-mediated differentiation
of ES cells [103]. Likewise, treatment of human ES cells with Nutlin, a small molecule that binds to
the p53 antagonist Mdm2 and inhibits p53 degradation resulting in p53 accumulation promoted the
differentiation of stem cells [104]. Maimets and coworkers assumed that the main mechanism that
is responsible for the differentiation of human ES cells after activation of p53 is the inhibition of S
phase entry into the cell cycle due to the induction of the cell cycle inhibitor p21 by p53. Other studies
showcasing p53−/− human ES cells further confirmed the suppressive activity of p53 for stem cell
pluripotency [102,105,106]. Of note, silencing Oct4 in human ES cells led to the activation of p53 and in
consequence to ES cell differentiation [107]. Silencing of Oct4, furthermore, reduced the expression
of Sirt1, a deacetylase known to inhibit p53 activity, leading to increased acetylation of p53 at lysine
120 and 164 which leads to stabilization and activation of p53 in human ES cells [107]. A very recent
report identified a regulatory network in mesendodermal differentiation of mouse and human ES cells
involving other members of the p53 family (p63 and p73) [108]. They showed p53, p63, and p73 are
crucial for the activation of eomesodermin, Foxa2 (forkhead box A2) and goosecoid which support
the differentiation into mesendoderm of ES cells in vitro and in the embryo. p53 family members
directly control the activation of these genes by governing the cooperation of Wnt and nodal which are
interdependent in driving mesendodermal differentiation of pluripotent cells [108].
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In adult stem cells including neural and hematopoietic stem cells, p53 negatively regulates
proliferation and self-renewal and helps to maintain the quiescent state [109,110]. More recently, it
was uncovered that p53 loss had a pro-osteogenic function in primary mouse bone marrow stem
cells, where p53 indirectly repressed the expression of Runx2 (runt related transcription factor 2) by
activating the miRNA-34 family [111]. Furthermore, this lineage specification role for p53 appeared to
be conserved in human osteosarcoma cells [111].
6. p53 in Amniotic Fluid Stem Cells
While the role of p53 has been investigated in ES cells and adult stem cells as described above,
only little was known about the regulation and function of p53 in AFS cells in the past. Recently, our
group investigated p53 protein levels, p53 localization, and p53 activity during Cell Prolif.eration,
differentiation, and during the DNA damage response in human AFS cells [112].
Earlier reports showed both constant stable expression and also downregulation of p53 mRNA
during long term passaging of AFS cells and AF mesenchymal stromal/stem cells [14,113,114]. In our
hands, expression of p53 did not change with increased passaging numbers of AFS cells, which is
consistent with the studies of Poloni et al. and Phermthai et al. [14,113]. In contrast to our study,
Savickiene et al., reported increased expression of p53 and its target gene p21 during the propagation of
AFS cells from passages 3–9 [115]. This increase in p53 levels was associated with cellular senescence
as assessed by monitoring the β-galactosidase activity while we did not observe an increase in cellular
senescence with increased propagation of our AFS cells. The reason for these contradictory results is,
however, unknown. We furthermore found that undifferentiated AFS cells express p53 at lower levels
than in cancer cells and that the p53 protein in AFS cells is mainly localized in the nucleus. However,
despite its nuclear localization, the anti-proliferative activity of p53 is compromised in these cells as it
has been seen previously in ES cells [92,112].
When we treated AFS cells with retinoic acid to induce neural differentiation, we observed an
increase in p53 protein levels [112] which is consistent with the studies of Thangnipon et al. and
Gasiu¯niene˙ et al. Thangnipon and his crew observed increased p53 levels when they induced neuronal
differentiation of AFS cells with a combination of N-benzylcinnamide and bone morphogenetic protein
(BMP)-9 [116] whereas Gasiu¯niene˙ and colleagues observed an increase in p53 mRNA and protein
levels upon cardiomyogenic differentiation in AFS cells using DNMT methyltransferases and p53
inhibitors [117]. We could furthermore show that p53 is an important determinant for the DNA
damage response of AFS cells. Upon DNA damage, p53 becomes activated in AFS cells and leads to
the transcriptional activation of its target genes p21 and mdm2 [112]. In addition, nuclear staining for
the DNA damage marker γ-H2AX was negative in normal AFS cells in comparison to cells whose
DNA was damaged with etoposide [112].
7. Concluding Remarks
AFS cells are emerging as an alternative source of stem cells with promising advantages for
disease modeling and applications in regenerative medicine, although there are still questions to
address regarding their safety and potential, and p53 may play important roles in these processes.
As the amniotic fluid contains a heterogeneous population of cells, in many studies, mixtures of
unselected, non-clonal cells have been used, causing conflicting results and uncertainty regarding the
identity of the cell population employed. However, stem cells within the amniotic fluid do possess a
high proliferation rate, clonogenicity, and a broad differentiation potential ranging from multipotent
cells to unipotent committed progenitors. The therapeutic potential of AFS cells has been shown in
experimental models of diseases of the lung, heart, skeletal muscle, bone, cartilage, kidney, blood and
nervous system. Since AFS cells are primary cells of a very early stage of human development, these
cells are also interesting as a model system for basic research. Finally, although AFS cells have profiles
similar to ES and adult stem cells, it is quite surprising why these cells are not tumorigenic when
transplanted into immune-compromised animals. p53, which is already known to be an important
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tumor suppressor protein in pluripotent stem cells and differentiated cells, may be considered as a
crucial control point in AFS cells as well. Therefore, it is essential to identify if p53 is involved not only
in the processes underlying the ‘stemness’ of AFS cells but also in their tumorigenicity.
p53’s role in tumorigenesis is widely known with thousands of publications and an increasing list
of p53 targets and effector functions, making it even more difficult to understand the complexity and
reach of this single protein. Interest is also driven to focus on potential mechanistic links between the
loss of p53 and the stem cell–like cellular plasticity which has been suggested to contribute to tumor cell
heterogeneity and to drive tumor progression. We now know that p53 is actively present and involved
in a variety of cellular processes in AFS cells, but its involvement is less well understood. Does p53
play a different cellular function in AFS cells? Is p53 essential for tumor suppressive functions in AFS
cells? Does the loss of p53 in AFS cells lead to tumor formation? These are yet unanswered questions,
the knowledge of which could potentially improve the usage of AFS cells for therapy in the future.
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